- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Placebo, Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 57
- States / cities
- North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 1,849
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hereditary Cancer Syndrome
- Interventions
- Modified genetic counseling, Traditional genetic counseling
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 967 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Portland, Oregon
- Conditions
- Mucopolysaccharidosis Type IH, MPS I, Hurler Syndrome
- Interventions
- Laronidase
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema, Corneal Dystrophy, Corneal Ulcer, Foreign Body in Cornea, Bell Palsy, Keratoconjunctivitis, Filamentary Keratitis, Sicca Syndrome; Keratoconjunctivitis (Etiology)
- Interventions
- Lotrafilcon A contact lenses
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Franklin Park, Illinois • Memphis, Tennessee
- Conditions
- Laxity; Skin
- Interventions
- AGE Serum
- Other
- Lead sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
- Other
- Eligibility
- 25 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Atopic Dermatitis
- Interventions
- PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Oculocutaneous Albinism
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Year to 80 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Port Wine Stain, Nevus of Ota, Tattoos, Scars, Acne, Hypertrichosis, Sebaceous Gland Diseases
- Interventions
- Optical Clearing
- Device
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Healthy Volunteers
- Interventions
- Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Neurofibromatosis Type 1, Neurofibromatosis 1, Neurofibromatosis (Nonmalignant), Cutaneous Neurofibroma
- Interventions
- Evaluation of the natural history of cutaneous neurofibromas
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 1 Year to 100 Years
- Enrollment
- 500 participants
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- atorvastatin
- Drug
- Lead sponsor
- The Center for Rheumatic Disease, Allergy, & Immunology
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Skin Laxity
- Interventions
- Dermal Handpiece
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Ichthyosis
- Interventions
- Observation
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 3 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Stenosis, Histiocytoma
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years to 90 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Achondroplasia
- Interventions
- Recifercept
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 15 Months to 12 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Irvine, California • Long Beach, California • Torrance, California + 2 more
- Conditions
- Psoriasis, Atopic Dermatitis
- Interventions
- CT-100-004-A, CT-100-004-B
- Device
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dermatitis Atopic
- Interventions
- Blood sample, Cheek swab
- Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 0 Years to 11 Years
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Los Angeles, California + 16 more
- Conditions
- Atopic Dermatitis, Type 1 Hypersensitivity
- Interventions
- STMC-103H, Placebo
- Biological
- Lead sponsor
- Siolta Therapeutics, Inc.
- Industry
- Eligibility
- 0 Days to 14 Days
- Enrollment
- 283 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Joint Disease
- Interventions
- Total Knee Arthroplasty (EVOLUTION®)
- Device
- Lead sponsor
- MicroPort Orthopedics Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Morton Grove, Illinois
- Conditions
- Atopic Dermatitis
- Interventions
- CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 14
- States / cities
- Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
- Conditions
- Acute Intermittent Porphyria (AIP)
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Marfan Syndrome
- Interventions
- Atenolol, Losartan
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atopic Dermatitis
- Interventions
- Fluocinonide
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Narrative Medicine, Chronic Disease, Terminal Illness, Cancer, Diabetes Mellitus, Cystic Fibrosis, Rheumatologic Disorder, Oncologic Disorders, Hematologic Diseases
- Interventions
- Patient Provider Orientation Scale, Interview performed by MHP student
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 8 Years to 100 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Gainesville, Florida